Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

被引：0

作者：

Dimitrios Pectasides

Vasilios Karavasilis

George Papaxoinis

Georgia Gourgioti

Thomas Makatsoris

Georgia Raptou

Eleni Vrettou

Joseph Sgouros

Epaminontas Samantas

George Basdanis

Pavlos Papakostas

Dimitrios Bafaloukos

Vassiliki Kotoula

Haralambos P. Kalofonos

Chrisoula D. Scopa

George Pentheroudakis

George Fountzilas

机构：

[1] “Hippokration” Hospital,Oncology Section, Second Department of Internal Medicine

[2] Aristotle University of Thessaloniki School of Medicine,Department of Medical Oncology, “Papageorgiou” Hospital

[3] Section of Biostatistics,Division of Oncology, Department of Medicine

[4] Hellenic Cooperative Oncology Group,Department of Pathology

[5] Data Office,Third Department of Medical Oncology

[6] University Hospital,First Propaedeutic Department of Surgery, “AHEPA” Hospital

[7] University of Patras Medical School,Department of Medical Oncology

[8] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology

[9] “Agii Anargiri” Cancer Hospital,Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research

[10] Aristotle University of Thessaloniki School of Medicine,Department of Pathology

[11] “Hippokration” Hospital,Department of Medical Oncology

[12] “Metropolitan” Hospital,undefined

[13] Aristotle University of Thessaloniki School of Medicine,undefined

[14] University Hospital,undefined

[15] University of Patras Medical School,undefined

[16] Ioannina University Hospital,undefined

来源：

BMC Cancer | / 15卷

关键词：

Colorectal cancer; Adjuvant chemotherapy; Modified FOLFOX6; Capecitabine; Oxaliplatin; Prognosis; KRAS; Microsatellite instability;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer: YCOG1402 (SOAP trial)
Suwa, Yusuke
Watanabe, Jun
Suwa, Hirokazu
Ozawa, Mayumi
Momiyama, Masashi
Ishibe, Atsushi
Nagamine, Kotaro
Yamagishi, Shigeru
Ota, Mitsuyoshi
Fukushima, Tadao
Sekido, Hitoshi
Saigusa, Yusuke
Endo, Itaru
ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (06): : 922 - 931
[42] Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months
Franken, Ingrid A.
van der Baan, Frederieke H.
Vink, Geraldine R.
May, Anne M.
van Grevenstein, Wilhelmina M. U.
Koopman, Miriam
Roodhart, Jeanine M. L.
EUROPEAN JOURNAL OF CANCER, 2024, 208
[43] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
Kyung-Ha Lee
In Jun Yang
Gi Won Ha
Jaeim Lee
Youn Young Park
Suk Hwan Lee
Jong Min Lee
Jung Hoon Bae
Eun Jung Park
Hyungjin Kim
Keun Young Kim
Sanghyung An
Ik Yong Kim
Ji Yeon Kim
BMC Cancer, 24
[44] Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial
Tsuchiya, Takashi
Sadahiro, Sotaro
Sasaki, Kazuaki
Kondo, Ken
Katsumata, Kenji
Nishimura, Genichi
Kakeji, Yoshihiro
Baba, Hideo
Morita, Takayuki
Koda, Keiji
Sato, Seiji
Matsuoka, Junji
Yamaguchi, Yoshiyuki
Usuki, Hisashi
Hamada, Chikuma
Kodaira, Susumu
Saji, Shigetoyo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) : 1253 - 1261
[45] The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
Andre, Thierry
Iveson, Timothy
Labianca, Roberto
Meyerhardt, Jeffrey A.
Souglakos, Ioannis
Yoshino, Takayuki
Paul, James
Sobrero, Alberto
Taieb, Julien
Shields, Anthony F.
Ohtsu, Atsushi
Grothey, Axel
Sargent, Daniel J.
CURRENT COLORECTAL CANCER REPORTS, 2013, 9 (03) : 261 - 269
[46] Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
Kotaka, Masahito
Yoshino, Takayuki
Oba, Koji
Shinozaki, Katsunori
Touyama, Tetsuo
Manaka, Dai
Matsui, Takanori
Ishigure, Kiyoshi
Hasegawa, Junichi
Inoue, Keiji
Goto, Koichi
Sakamoto, Junichi
Saji, Shigetoyo
Ohtsu, Atsushi
Watanabe, Toshiaki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 75 - 84
[47] Mature Results of a Prospective Randomized Trial Comparing 5-Flourouracil with Leucovorin to 5-Flourouracil with Levamisole as Adjuvant Therapy of Stage II and III Colorectal Cancer-The Israel Cooperative Oncology Group (ICOG) Study
Figer, Arie
Nissan, Aviram
Shani, Adi
Borovick, Riva
Stiener, Mariana
Baras, Mario
Freund, Herbert R.
Sulkes, Aaron
Stojadinovic, Alexander
Peretz, Tamar
JOURNAL OF CANCER, 2011, 2 : 177 - 185
[48] Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial
Takashi Tsuchiya
Sotaro Sadahiro
Kazuaki Sasaki
Ken Kondo
Kenji Katsumata
Genichi Nishimura
Yoshihiro Kakeji
Hideo Baba
Takayuki Morita
Keiji Koda
Seiji Sato
Junji Matsuoka
Yoshiyuki Yamaguchi
Hisashi Usuki
Chikuma Hamada
Susumu Kodaira
Shigetoyo Saji
Cancer Chemotherapy and Pharmacology, 2014, 73 : 1253 - 1261
[49] Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool
Lin, Jen-Kou
Tan, Elise Chia-Hui
Yang, Ming-Chin
HEALTH AND QUALITY OF LIFE OUTCOMES, 2015, 13
[50] Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study
Nagasaka, Takeshi
Mishima, Hideyuki
Sawaki, Akira
Shimokawa, Mototsugu
Inukai, Michio
Shinozaki, Katsunori
Tanioka, Hiroaki
Nasu, Junichiro
Nishina, Tomohiro
Hazama, Shoichi
Okajima, Masazumi
Yamaguchi, Yoshiyuki
BMJ OPEN, 2016, 6 (06):

← 1 2 3 4 5 →